Personalis (NASDAQ:PSNL) Shares Up 8.1% – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL) shot up 8.1% during mid-day trading on Wednesday . The company traded as high as $10.93 and last traded at $10.8740. Approximately 332,454 shares traded hands during trading, a decline of 83% from the average daily volume of 1,942,976 shares. The stock had previously closed at $10.06.

Analyst Ratings Changes

A number of research firms recently commented on PSNL. Needham & Company LLC upped their price objective on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Morgan Stanley cut their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, BTIG Research decreased their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Price Performance

The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -10.52 and a beta of 2.28. The stock has a 50 day moving average price of $8.07 and a two-hundred day moving average price of $8.23.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. As a group, research analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher M. Hall sold 80,091 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $11.02, for a total transaction of $882,602.82. Following the sale, the chief executive officer directly owned 235,986 shares in the company, valued at $2,600,565.72. This represents a 25.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $12.01, for a total transaction of $480,400.00. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,387,984.33. This represents a 16.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,799 shares of company stock worth $2,031,692 over the last quarter. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Personalis

A number of hedge funds have recently added to or reduced their stakes in PSNL. T. Rowe Price Investment Management Inc. increased its position in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after acquiring an additional 7,896,714 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after purchasing an additional 1,347,439 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares during the period. Aberdeen Group plc increased its holdings in Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares during the period. Finally, ARK Investment Management LLC raised its position in Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after purchasing an additional 802,268 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.